GXV-813

GXV-813, also known as EX-A8078, is a muscarinic acetylcholine M 4 receptor agonist which is under development for the treatment of schizophrenia.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

GXV-813, also known as EX-A8078, is a muscarinic acetylcholine M 4 receptor agonist which is under development for the treatment of schizophrenia. It is taken orally. The drug is under development by Novartis.

As of March 2026, it is in phase 2 clinical trials for schizophrenia. The drug also is or was under development for another unspecified indication, but no recent development for this use has been reported. Two phase 2 trials for schizophrenia are underway and expected to be completed in April 2027.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372021107 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001372021107 · captured 2026-08-29 · ledger · version history

Cite this page as: encyclopegia.org, “GXV-813”, snapshot enwiki-001372021107. https://encyclopegia.org/a/gxv-813

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.